Penumbra Stock

Penumbra FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Penumbra (PEN) as of Aug 11, 2026 is 98.45 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 1,051.23 % — a change of -90.63% (lower).

FCF Conversion

98.45 %

YoY

-90.63%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Penumbra is 2026 98.45 % . FCF Conversion Rate (FCF/EBITDA) of Penumbra was 2025 1,051.23 % . It decreases by -90.63% lower compared to the previous year.
Access this data via the Eulerpool API

Penumbra Stock analysis

What does Penumbra do? Penumbra Inc is an American company specializing in medical technology. It was founded in 2004 and is headquartered in Alameda, California. The company has branches and subsidiaries worldwide. It offers various products for the treatment of strokes, aneurysms, vascular injuries, and other medical conditions. The history of Penumbra Inc began with the founder and CEO Adam Elsesser's vision to develop innovative technologies to help patients with challenging medical conditions. The company started with just one product, the Penumbra 3D Coiling Technology, which is used for the treatment of brain aneurysms. Penumbra Inc's business model is based on the development and marketing of innovative medical devices and technologies to assist surgeons and specialists in treating their patients better. The company conducts intensive research and development to create new products that meet market demand. Penumbra Inc is divided into different divisions to offer a comprehensive range of medical tools and devices to its customers. The main divisions of the company are Neuro, Vascular, and Oncology. Under the Neuro division, Penumbra Inc offers a wide range of devices and technologies for the treatment of strokes and trauma. This includes the Penumbra Coil 400, used for treating intracranial aneurysms, and the Penumbra Jet 7 Reperfusion Catheter, an innovative technology for restoring blood flow in stroke patients' brains. The Vascular division of Penumbra Inc provides devices for the treatment of vascular diseases, such as endovascular repairs of aortic aneurysms. This division utilizes the innovative Penumbra SMART Coil technology, which provides improved handling and safety. The Oncology division of Penumbra Inc focuses on developing technologies to enhance healthcare for cancer patients. This includes innovative drug delivery devices, such as the Penumbra System used in brachytherapy. Penumbra Inc is a leading provider of medical devices and technologies used in the treatment of complex medical conditions. Over the past decade, the company has established its reputation in the industry. Continuous investment in research and development and a focus on patient and medical professionals' needs have solidified Penumbra Inc's success in the international market. Penumbra is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Penumbra stock

FCF Conversion Rate (FCF/EBITDA) of Penumbra is 98.45 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Penumbra changed from 1,051.23 % to 98.45 %, representing a -90.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Penumbra since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Penumbra with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Penumbra

All Key Metrics — Penumbra